MX2020011190A - Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. - Google Patents
Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.Info
- Publication number
- MX2020011190A MX2020011190A MX2020011190A MX2020011190A MX2020011190A MX 2020011190 A MX2020011190 A MX 2020011190A MX 2020011190 A MX2020011190 A MX 2020011190A MX 2020011190 A MX2020011190 A MX 2020011190A MX 2020011190 A MX2020011190 A MX 2020011190A
- Authority
- MX
- Mexico
- Prior art keywords
- angiotensin
- mcg
- dose
- equivalent
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere, por ejemplo, a un método que comprende administrar a un individuo que tiene choque de gasto elevado y someterlo a tratamiento con una catecolamina a una dosis equivalente a por lo menos aproximadamente 0.2 mcg/kg/min de norepinefrina de una dosis de angiotensina II que es efectiva para elevar la presión sanguínea del individuo hasta una presión arterial promedio (MAP) de aproximadamente 65 mm de Hg o más, y la cual es efectiva para reducir la dosis de la catecolamina requerida para mantener una MAP de aproximadamente 65 mm de Hg hasta el equivalente de aproximadamente 0.05-2.0 mcg/kg/min de norepinefrina o menos, o hasta el equivalente de aproximadamente 0.05 mcg/kg/min de norepinefrina o menos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917576P | 2013-12-18 | 2013-12-18 | |
| US201461955706P | 2014-03-19 | 2014-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011190A true MX2020011190A (es) | 2020-11-13 |
Family
ID=53367119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008108A MX2016008108A (es) | 2013-12-18 | 2014-12-18 | Angiotensina ii sola o en combinacion para el tratamiento de hipotension. |
| MX2020011190A MX2020011190A (es) | 2013-12-18 | 2016-06-17 | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008108A MX2016008108A (es) | 2013-12-18 | 2014-12-18 | Angiotensina ii sola o en combinacion para el tratamiento de hipotension. |
Country Status (23)
| Country | Link |
|---|---|
| US (7) | US9220745B2 (es) |
| EP (2) | EP2986308B1 (es) |
| JP (3) | JP6824739B2 (es) |
| KR (3) | KR20230051721A (es) |
| CN (3) | CN112546197A (es) |
| AU (2) | AU2014364528C1 (es) |
| BR (1) | BR112016013961A2 (es) |
| CA (1) | CA2933601A1 (es) |
| CY (1) | CY1122604T1 (es) |
| DK (1) | DK2986308T3 (es) |
| EA (1) | EA037823B1 (es) |
| ES (1) | ES2771749T3 (es) |
| HR (1) | HRP20200009T1 (es) |
| HU (1) | HUE047062T2 (es) |
| IL (1) | IL246162B (es) |
| LT (1) | LT2986308T (es) |
| MX (2) | MX2016008108A (es) |
| NZ (1) | NZ721089A (es) |
| PL (1) | PL2986308T3 (es) |
| PT (1) | PT2986308T (es) |
| RS (1) | RS59804B1 (es) |
| SI (1) | SI2986308T1 (es) |
| WO (1) | WO2015095535A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| ES2771749T3 (es) | 2013-12-18 | 2020-07-07 | The George Washington Univ A Congressionally Chartered Not For Profit Corporation | Angiotensina II en combinación para el tratamiento de hipotensión |
| SG11201610897VA (en) * | 2014-07-08 | 2017-01-27 | Jolla Pharma | Methods for treating hypotension |
| WO2016153558A1 (en) | 2015-03-20 | 2016-09-29 | Atkinson Arthur J | Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
| KR20180108630A (ko) * | 2016-01-07 | 2018-10-04 | 라 졸라 파마슈티칼 컴파니 | 혈관수축제의 투여 방법 |
| CA3010781A1 (en) | 2016-01-07 | 2017-07-13 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| TW201927331A (zh) * | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
| WO2023244552A1 (en) * | 2022-06-15 | 2023-12-21 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
| US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| WO2002098906A1 (en) | 2001-06-04 | 2002-12-12 | Human Genome Sciences, Inc. | Methods and compositions for modulating ace-2 activity |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| JP2007510643A (ja) | 2003-11-06 | 2007-04-26 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 医薬化合物 |
| NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
| FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
| EP1942985B1 (en) | 2005-09-29 | 2011-04-27 | Fibrogen, Inc. | Methods for reducing blood pressure |
| AU2006332449B2 (en) * | 2005-12-30 | 2008-05-15 | Howard Florey Institute Of Experimental Physiology And Medicine | A method of treatment |
| US20070293552A1 (en) | 2006-06-15 | 2007-12-20 | Gorczynski Richard J | Antihypertensive therapy method |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| BRPI0719319A2 (pt) | 2006-11-17 | 2014-02-04 | Da Volterra | Liberação colônica usando contas de zn/pectina com um revestimento de eudragit |
| WO2009009907A1 (en) | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| EP2350649A4 (en) | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
| US9572856B2 (en) * | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| KR20130026504A (ko) | 2010-07-14 | 2013-03-13 | 큠버랜드 에멀징 테크놀로지스 아이앤씨 | 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법 |
| EP3858437A1 (en) | 2013-04-26 | 2021-08-04 | La Jolla Pharma, LLC | Compositions and methods for treating renal failure |
| ES2771749T3 (es) | 2013-12-18 | 2020-07-07 | The George Washington Univ A Congressionally Chartered Not For Profit Corporation | Angiotensina II en combinación para el tratamiento de hipotensión |
| US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
| SG11201610897VA (en) | 2014-07-08 | 2017-01-27 | Jolla Pharma | Methods for treating hypotension |
| KR20180108630A (ko) | 2016-01-07 | 2018-10-04 | 라 졸라 파마슈티칼 컴파니 | 혈관수축제의 투여 방법 |
| CA3010781A1 (en) | 2016-01-07 | 2017-07-13 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| US11583568B2 (en) | 2017-04-14 | 2023-02-21 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| TW201927331A (zh) | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
-
2014
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en active Application Filing
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Application Discontinuation
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 MX MX2016008108A patent/MX2016008108A/es unknown
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 EP EP19197866.7A patent/EP3607962A1/en active Pending
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active IP Right Grant
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko active Application Filing
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-03 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en active Pending
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja active Pending
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011190A (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| MX365950B (es) | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| PH12015502075B1 (en) | Treatment of cataplexy | |
| NZ774222A (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| WO2014107685A3 (en) | Compositions and methods for using huperzine and analogs thereof | |
| MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| MX2018001684A (es) | Metodo de curacion de heridas. | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| MX2016006256A (es) | Tratamiento de glaucoma usando laquinimod. | |
| EA202092463A1 (ru) | Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии | |
| MX2021001394A (es) | Metodo para mejorar la eficacia de un agente anticanceroso. | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний | |
| PH12017501918A1 (en) | Multi-peptide composition | |
| EA201892389A1 (ru) | Офтальмологическая композиция, содержащая синергическую комбинацию гликогена и гиалуроновой кислоты или ее соли | |
| EA201991119A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| AR110086A1 (es) | Combinación de un inhibidor de t790m de efgr y un inhibidor de cdk para el tratamiento de cáncer de pulmón de células no pequeñas | |
| UA106472U (uk) | Засіб для лікування дерматологічних захворювань | |
| UA102764U (uk) | Спосіб лікування гіповолемії у хірургічних хворих |